Presentation ACC 2024 Primary Results from the Phase 2 KARDIA-2 Study Presenter: Akshay Desai April 07, 2024 REGISTER for free or LOG IN to view this content Clinical Cardiology Clinical Pharma Hypertension Presentation ACC 2024 Up Next Presentation ACC 2024 Randomized, Double-blind, Placebo-controlled, Phase 3, Study To Evaluate Lerodalcibep Long-term Efficacy And Safety In Patients With, Or At Very-high Or High Risk, For Cardiovascular Disease On Stable Lipid-lowering Therapy Presenter: Eric Quinton Klug April 07, 2024 More slides + Presentation ACC 2024 Percutaneous Transvalvular Micro axial Flow Pump in Infarct Related Cardiogenic Shock Presenter: Jacob Eifer Møller April 07, 2024 Presentation ACC 2024 Principal Results From the Double-blind, Placebo-controlled ULTIMATE-DAPT Trial Presenter: Gregg W Stone April 07, 2024 We Recommend
Presentation ACC 2024 Randomized, Double-blind, Placebo-controlled, Phase 3, Study To Evaluate Lerodalcibep Long-term Efficacy And Safety In Patients With, Or At Very-high Or High Risk, For Cardiovascular Disease On Stable Lipid-lowering Therapy Presenter: Eric Quinton Klug April 07, 2024
Presentation ACC 2024 Percutaneous Transvalvular Micro axial Flow Pump in Infarct Related Cardiogenic Shock Presenter: Jacob Eifer Møller April 07, 2024
Presentation ACC 2024 Principal Results From the Double-blind, Placebo-controlled ULTIMATE-DAPT Trial Presenter: Gregg W Stone April 07, 2024